Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tempus AI
TEM
5
Life360
LIF
US Stock MarketDetailed Quotes
Cardiff Oncology (CRDF)
- 3.650
- -0.010-0.27%
Close Jul 7 16:00 ET
- 3.652
- +0.002+0.05%
Post 20:01 ET
242.82MMarket Cap-3.92P/E (TTM)
3.829High3.650Low994.06KVolume3.700Open3.660Prev Close3.71MTurnover1.66%Turnover RatioLossP/E (Static)66.53MShares5.64052wk High3.43P/B218.27MFloat Cap2.01052wk Low--Dividend TTM59.80MShs Float81.480Historical High--Div Yield TTM4.90%Amplitude0.450Historical Low3.728Avg Price1Lot Size
About Cardiff Oncology Company
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Company Profile
SymbolCRDF
Company NameCardiff Oncology
Listing DateJul 31, 2003
ISINUS14147L1089
Founded1999
CEODr. Mark Erlander, PhD
MarketNASDAQ
Employees33
Fiscal Year Ends12-31
Address11055 Flintkote Avenue
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-952-7570
Company Executives
- Name
- Position
- Salary
- Dr. Mark Erlander, PhD
- Director and Chief Executive Officer
- 2.40M
- James E. Levine
- Chief Financial Officer and Principal Accounting Officer
- 1.27M
- Dr. Tod Smeal, PhD
- Chief Scientific Officer
- --
- Dr. Roger Sidhu
- Chief Medical Officer
- --
- Dr. Rodney S. Markin,M.D.,PhD
- Chairman of the Board
- 175.46K
- Lale White
- Independent Director
- 137.46K
- Dr. Renee P. Tannenbaum, D.Pharm.
- Independent Director
- 131.46K
- Dr. Mani Mohindru, PhD
- Independent Director
- 133.46K
- Dr. James O. Armitage,M.D.
- Independent Director
- 125.46K
- Dr. Gary W. Pace,PhD
- Independent Director
- 135.46K
Market Insights
AI application software AI application software
AI application software stocks refer to companies that utilize advanced algorithms and computing capabilities in the field of artificial intelligence to develop and provide innovative software solutions. Through the application of artificial intelligence technology, these companies have improved the efficiency and functionality of their products to meet the needs of different industries, such as automation, data analysis, customer service, etc. AI application software stocks refer to companies that utilize advanced algorithms and computing capabilities in the field of artificial intelligence to develop and provide innovative software solutions. Through the application of artificial intelligence technology, these companies have improved the efficiency and functionality of their products to meet the needs of different industries, such as automation, data analysis, customer service, etc.
Unlock Now
Discussing
The tariff deferral period has been extended! How have trade policies in various countries evolved?
On the 7th local time, U.S. President Trump signed an executive order extending the so-called "reciprocal tariff" delay period, postponing t
Food流油
Apr 14 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"